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Background: The detection of circulating tumour cells (CTC) in blood sample in patients
with early or advanced colorectal cancer has a potential prognostic value.
Methods: The challenge of CTC detection is related to the requirement of high sensitivity
combined with high specificity method. CTCs detection can be distinguished between
indirect and direct methods. The former ones are based on the recognition of tissue-,
organ- or tumour-specific markers by immuno-histochemistry (indirect immuno-medi-
ated methods) or (real-time) RT-PCR (indirect molecular methods), whilst the latter are
related to CTCs selection based on the physical properties of density and sizes. Ongoing
and future isolation by size of epithelial tumour cells (ISET) developments concerning
automated image analysis on the filter and transmission of high definition images
through the web for ‘on line’ cytopathological consultations are aimed to speed up the
work of cytopathologists on CTC/ circulating tumour microemboli (CTM) detection.
Conclusions: CTC detection in colorectal cancer (CRC) correlates with pathological stage
and clinical outcome in particular in those patients with advanced disease. CRC CTC
level before and after CT are an independent prognostic factor for progression-free and
overall survival. The positive prognostic value of complete clearance CTC after surgery
may be useful to select patients for adjuvant chemotherapy.
 2008 Elsevier Ltd. All rights reserved.patients that will benefit from adjuvant CT in this subgroup1. Introduction
Colorectal cancer (CRC) is the fourth most common malig-
nancy in the European Community and the second most
frequent cause of cancer-related death. Every year, about
213,000 cases of CRC will be diagnosed in Europe, and
110,000 people will die because of this.1 Approximately
70% of these cancers will arise in the colon, whereas 30%
will occur in the rectum. Significant progress in adjuvant
chemotherapy (CT) for stage III CRC has been achieved with
the addition of oxaliplatin to infusional 5-fluorouracil and
leucovorin. In stage II CRC the role of adjuvant CT is still
controversial. New prognostic factors are necessary to selecter Ltd. All rights reserved
7947298; fax: +39 55 7947
i.toscana.it, dicostanzofraof patients.
Over the past decade, many advances as in the under-
standing the metastatic CRC have reported, and the introduc-
tion of biologic therapies has increased the overall survival
(OS) over 25 months. Consequently, physicians have multiple
potential treatment options for patients with metastatic CRC.
The selection of patients through clinical and biological prog-
nostic factors to identify the best treatment for each patient
represents the principal end-point.
Preliminary data suggest that the level of circulating
tumour cells (CTC) detected in blood sample collected in
patients with early or advanced disease are a potential.
538.
ncesco@tiscali.it (F. Di Costanzo).
E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 5 2 –5 9 53prognostic factor. CTC count in the future could provide an
evidence of early treatment success or failure to guide treat-
ment decisions. The detection of CTC has been proposed as
a method to assess the response to treatment of metastatic
breast cancer (MBC). The detection of tumour cells may have
clinical utility in the risk stratification in early breast cancer,
in the early detection of relapse and in the monitoring of
the response to treatment.2 Cristofanilli et al. conducted a
prospective study of 177 women with MBC compared to 345
women without breast cancer to confirm the correlation be-
tween the level of detection of peripheral blood tumour cells
and the presence of metastatic breast disease.3 Patients were
tested prior to receiving breast cancer treatment and at the
first follow-up after the beginning of the treatment. Five or
more cells per 7.5 ml of blood were associated with poor
prognosis.
At the initial sampling, 50% of the women with MBC had
more than five CTC per sample, with an average progres-
sion-free survival (PFS) of less than 3 months and an OS of
10 months. Women who had less than five CTC per sample
had a PFS of 7 months and an OS of 18 months. Ten patients
died prior to the first follow-up; their cancer cell counts ran-
ged from 9 to 23,618 per sample. Only 30% of the women with
MBC had five or more cells per sample, with an average PFS of
2.1 months and OS of 8.2 months, compared to women who
had less than five CTC per sample, who had a PFS of 7 months
and an OS of greater than 18 months. The number of cells per
sample at follow-up was indicative of prognosis. Multivariate
analysis of clinical factors demonstrated that whilst clinical
factors (including time to metastasis, HER2/neu status and
type of therapy) still correlated to outcomes, the strongest
predictors of PFS and OS were the levels of CTCs at baseline
and at the first follow-up visit. Stathopoulou et al. described
a significant negative prognosis after detecting CTC by a cyt-
ocheratin 19 (CK19) reverse transcriptase-polymerase chain
reaction (RT-PCR) method in 128 breast cancer patients (stage
I/II).4 Patients, having CTC in blood after the removal of the
primary tumour and before receiving adjuvant therapy had
a significant lower survival time (risk factor 8.5) and a reduced
disease-free interval (DFI) (risk factor 5.1). It should be noted
that this was a patient group with a relatively favourable
prognosis. Therefore, the identification of CTC in these pa-
tients represents an important additional factor for deciding
about therapy.
Meropol et al., reported in 430 patients with advanced CRC
that the number of CTC, before and after the beginning of
therapy, is an effective, non invasive prognostic marker for
OS and PFS.5 They enroled in this preliminary trial patients
with measurable metastatic CRC before CT (first, second or
third line therapy). Peripheral blood was collected for CTC at
baseline and again at 1–2 weeks, 3–5 weeks, 6–12 weeks and
13–20 weeks after the beginning of the treatment.
Based upon a systematic evaluation of correlation with
imaging, they evaluated three CTC per 7.5 ml of blood as unfa-
vourable. In this study, 53% of patients had no detectable CTC
at baseline, and these patients had a better median OS (19
months) than patients with one or more CTC (12 months).
Twenty-six percent of patients had three or more CTC at base-
line. CTC and response rate (RR) were compared in the 320
evaluable patients. Clinical benefit (CB) [complete response(CR)+ partial response (PR) + stable desease (SD)] was obtained
in 93% of patients with fewer than three CTC, compared to 7%
of patients with three or more CTC. Thirty-eight patients
(11.8%) had an unfavourable number of CTC and 20 of them
(52.5%) had PD or died after the first assessment.
In patients that obtained a CB the median OS was 18.8
months in patients with fewer than three CTC and 7.1 months
for patients with at least three CTC respectively.
Also the analysis of PFS showed a better result in patients
with favourable number of CTC at baseline (7.9 months versus
4.5 months). In a multivariate analysis CTC was the best pre-
dictor of PFS and OS including other prognostic factors as
therapy, age, and performance status. In patients with ele-
vated CTC counts at baseline that obtained a reduction of
CTC after CT the OS increase to 11.0 months respect the pa-
tients that did not obtained this reduction (3.7 months).
Meropol et al., are also investigating if CTC could serve as a
source of tumour tissue for in vivo pharmacogenomic assay.
Sastre et al., reported in 97 patients with CRC stages I–IV
that the CTC detection correlates with pathological stage,
being significantly more frequent in those patients with ad-
vanced disease. Peripheral blood samples were collected for
CTC from 4 to 12 weeks after surgery and immediately before
adjuvant chemotherapy (if indicated) for patients with early-
stages and before palliative chemotherapy in those with ad-
vanced disease. Quantification of CTC in 7.5 ml of blood was
carried out with the semi-automated Cell Search System
(Veridex). The authors used the cut-off of 2 CTCs for 7.5 ml
of blood on the basis of previously reported date that estab-
lished that 2 or more CTC were only present in malignant epi-
thelial tumours.6 A parallel group of 30 healthy volunteers
were used as a control group.
Overall presence of 2 or more CTC was detected in 34
(36,2%) of 94 evaluated patients. The mean number of CTC
isolated was 3.4 (range 0-61). Correlation was not found
among positive CTC and location of primary tumour, in-
creased carcinoembryonic antigen (CEA) level, increased
LDH level and grade of differentiation.
Only stage correlated with positive CTC (20.7% in stage II,
24.1% in stage III and 60.7% in stage IV, P = 0.005). When a
threshold of 3 or more CTC was considered as positive, again
stage remained the only factor associated with CTC (12% in
stage II, 16% in stage III and 64% in stage IV, P = 0.0001). There
were no statistically significant differences between positive
CTC found in high risk stage II patients compared with those
in the low risk group (15.4% versus 25% P = 0.663). No CTCwere
found in the group of healthy volunteers.
The CTC detection cells search correlates with the stage,
but not with other clinical and morphological variables in pa-
tients with CRC. Colon cancer tumour cells are detectable in
all stages.
Allen-Mersh et al., assessed a potential role for RT-PCR
based CTC identification to predict CRC recurrence. mRNA
for CEA and cytocheratin (CK) 20 was identified by RT-PCR in
blood from patients with CRC, before and after primary tu-
mour resection.7 Cancer recurrence was assessed up, fol-
lowed-up and the accuracy of RT-PCR and primary tumour
lymph-node positivity in predicting recurrence was estimated
196 patients were evaluated. RT-PCR positivity within 24 h of
primary CRC resection is a strong predictor of CRC recurrence
54 E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 5 2 –5 9and may be useful clinically. In fact haematogenous metasta-
sis is an inefficient process, and most tumour cells apoptose
within 48 h of entering the circulation. CTC appear early in
the presence of an invasive solid tumour and disappear
rapidly after complete tumour removal. The present result
suggests that the estimation of tumour cells clearance from
the circulation within the first 24 h after primary CRC removal
could improve management decisions about adjuvant CT and
intensity of follow-up.
Hauchs et al., evaluated the clinical significance of CTC in
breast cancer and CRC patients. Systematic changes in the
expression profile of CTC in colorectal patients at different
stages of disease were observed; EGFR was expressed in 90%
of patients with CTC during primary disease whilst the
expression level decreased to 15% in CTC of metastatic pa-
tients. The expression of CEAwas low in CTC found after pri-
mary surgery (15%) and dominant in CTC of metastatic
patients (80%). The molecular profiling of CTC may be used
to identify therapeutic targets such as HER-2 or EGRF for per-
sonalised treatment.8
Hendlisz et al., at ASCO 2008 evaluated the impact of CT
on the EGFR expression of CTC in comparison to the pri-
mary tumour EGFR status. Peripheral blood was collected
from chemonaive patients with metastatic CRC, at baseline,
before the second cycle and after four CT cycles. CTC were
detected by using immuno-magnetic separation and immu-
no-fluorescent identification (cell search system, Veridex).
The EGFR status in CTC was determined by immuno-fluo-
rescent labelling. Fourteen (64%) patients had positive EGFR
CTC at baseline, no correlation was found between the
EGFR status of the primitive tumours and baseline CTC.
Fourteen patients had baseline CTC EGFR positive, after four
cycles of CT 13 patients had CTC EGRF positive, with med-
ian time to progression of 6.6 months (95% CI: 4–8.2), whilst
8 patients had baseline CTC EGFR negative, after 4 cycles of
CT, 7 patients had CTC EGFR positive, with median TTP of
8.5 months (95% CI: 7.5–9.5), log rank test: P = 0.04. The
study shows that CT administration induces changes in
the EGFR status of CTC. EGFR negative tumours should be
retested for EGFR status after CT, and the EGFR expression
of CTC in metastatic CRC could be useful in predicting out-
come under CT.9
Madajewicz et al., at ASCO 2008 presented a prospective
two-centre study, to define a CTC gene expression signature
that exhibits high detection specificity and sensitivity for
CRC patients. A viable cell isolation system that utilises the
invasiveness of tumour cells to a cell adhesion matrix was
used to enrich CTC. The samples were examined for gene
expression profiling using the Affimetrix microarray Hu
133A chip. The author identified a potentially specific CRC
CTC signature, and the diagnostic value, the role as a prog-
nostic and therapeutic marker will be evaluated in further
studies.102. CTC detection and methods
The challenge of CTC detection is related to the requirement
of high sensitivity combined with high specificity. Since inva-
sion can start very early during tumour development, identi-fication and counting of CTC when they are very rare (few
CTC per 10 ml of blood, which means few CTC mixed with
approximately 100 million leucocytes and 50 billion erythro-
cytes) could alert the oncologist about a developing tumour
invasion process.
Specificity is also an absolute requirement in this field. In
fact, a wrong identification of ‘non-tumour cells’ (like epithe-
lial non-tumour cells) as ‘tumour cells’, could generate poor
clinical and therapeutical choices having a negative impact
on the quality and/or expectancy of life in patients with
cancer.
Several recent reviews concerning the detection of CTC are
available.11–15 Many different methods have been developed
and some are commercially available. All of them possess
advantages and disadvantages. One of the main aims of this
manuscript is also to review the performance of some of
themost reliable procedures for CTC detection in an appropri-
ate clinical study.
A classification of methods for CTCs detection mainly dis-
tinguishes between cytometric and nucleic-acid-based tech-
niques16 on the basis of the methods used for CTCs
detection. The cytometric approaches use immuno-cyto-
chemical methods to identify single cells or groups of them,
whilst the latter detect DNA or RNA sequences that are differ-
entially represented in tumour and normal cells.16 More re-
cently a classification17 which distinguish between indirect
and direct methods was proposed. The former ones are based
on the recognition of tissue-, organ- or tumour-specific mark-
ers by immuno-histochemistry (Indirect immuno-mediated
methods) or (real-time) RT-PCR (Indirect molecular methods),
whilst the latter are related to CTCs selection based on phys-
ical properties of density and sizes (Table 1). The major disad-
vantage of the indirect approach relies in the difficulty of
demonstrating the cancerous nature of the cells or of their
cell-related signal without any doubt.3. Indirect molecular method
The main advantage of indirect molecular methods is sensi-
tivity which is considered to be higher than the reported sen-
sitivity of immuno-mediated detection and immuno-
cytochemistry.18 Currently two types of markers are used: epi-
thelial markers and ‘cancer specific’ markers. The first should
be expressed by all tumours of epithelial origin, but in partic-
ular conditions their expression can be activated also in blood
nucleated cells.19 In addition the expression of epithelial
markers can be lost by tumour cells through the process
called epithelial-to-mesenchymal transition (EMT) with obvi-
ous consequence on CTC number determination.20,21 On the
other hand, the list of cancer cell-specific markers is exten-
sive and expanding rapidly22, but due to the neoplastic heter-
ogeneity there are currently no universally expressed
markers in all tumour cells from a particular tumour type.23
Various genetic markers including k-ras point mutations,
CEA and cytokeratin 20 (CK20) have been used for detection
of CTC in the peripheral blood of patients with CRC. The
simultaneous use of multiple markers24,25 reflects more accu-
rately the presence of CTC into the blood stream. The high
sensitivity of RT-PCR carries the risk of post-amplification car-
Table 1 – In vitro methods for circulating tumour cell detection
Method classification
Molecular methods RNA Epithelial marker
Tumour-specific marker
Multi-marker
DNA Mutation analysis
Epigenetic markers
LOH
FISH
CGH
Array
Immuno-mediated methods Marker proteins Antibodies and immunomagnetic separation
(CellSearchTM, CTC-chip)
Density gradient and immuno-labelling
Flow cytometry
Isolation based on physical and morphological features Density gradient (Oncoquick)
Filtration (ISET, chip)
Blood smear
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positive PCR signals.
Quantitative RT-PCR (q-PCR) assays have been used to im-
prove both sensitivity and specificity of conventional RT-PCR
methods by means of fluorescent probes that specifically
hybridise to the amplified sequence. The q-PCR assays main
advantage relies just in the quantitative approach which al-
lows to define a cut-off value of a given transcript marker,
compared to a reference marker expressed in any cell. How-
ever, the proportion of tumour cells in blood may be highly
variable and the RT step introduces significant variability
making it problematic to define a relevant quantitative ‘cut-
off’ point.26 Technical problems related to qPCR assay reliabil-
ity have been discussed elsewhere27–30 and are beyond the
aim of this manuscript. Cell enrichment by immuno-mag-
netic techniques was also used prior to RNA extraction and
qPCR to improve assay specificity.31 An alternative molecular
approach to qPCR was also reported32 by using oligonu-
cleotide probes and alkaline phosphatase detection for
simultaneous evaluation of mRNA CTC target genes in a
high-throughput colorimetric membrane-array.
4. Indirect immuno-mediated method
Immuno-mediated detection is performed by immuno-label-
ling of cells enriched by immuno-magnetic separation.33
Enrichment of CTC can be obtained by commercially available
immuno-magnetic methods which provides a high enrich-
ment and thus leads to increased sensitivity of detection. They
also avoid cell lysis, which characterises the RT-PCR tests and
thus allows the counting of target cells. Some aspects should
be considered when using these methods for detection of
CTC. For instance, since specific antigens characterising CTC
are not known at present (antigens expressed by the tumour
cells from a solid tumour type and not expressed by leuco-
cytes), the authors have used antigens specific for epithelial
cells to isolate CTC [EpCAM, BerEP4, CK].34–37 Epithelial-spe-
cific antibodies can label non-tumour epithelial cells by
specific labelling and non-tumour non-epithelial cells by
non-specific labelling, thus giving false positive results. Small
numbers of epithelial cells38,39 have been found in peripheralblood of subjects without malignancy, being related to benign
epithelial proliferative diseases, inflammation, tissue trauma,
semi-surgical and surgical interventions. Organ-specific
markers have been used (antibodies to mammoglobulin,
PSA, CEA and HER-2)40,41 to identify CTC. However, false nega-
tive results can occur since these antigens are not present in
all tumour cells. Furthermore, some of these markers, mam-
moglobin and HER-2, are not entirely organ specific.42,43 Actu-
ally, no available antibody is 100% tumour or tissue-specific.
In the immuno-magnetic detection, whole blood or mono-
nuclear cells isolated by density gradient are put in contact
with magnetic particles (beads or ferrofluids)-bound antibod-
ies. Labelled cells are then collected by applying a magnetic
force whilst unlabelled cells remain in the supernatant and
are discarded. Since a large number of leucocytes still remain
trapped with the target cells, some methods include a ‘nega-
tive’ selection of leucocytes (i.e. with anti-CD 45) combined
with a ‘positive’ selection with antibodies to epithelial cells
(EpCAM, CK) (i.e.: CellSearchTM, VeridexTM). This procedure gets
rid of the majority of leucocytes but could detect non-malig-
nant epithelial cells and does not detect tumour cells which
do not express epithelial antigens. The CellSearch assay44
uses ferrofluids coated with EpCAM antibody (directed to a
cell adhesion molecule commonly expressed on normal and
malignant epithelial cells) to enrich epithelial cells. Cells are
then permeabilised, prefixed and labelled with the fluores-
cent nuclear dye DAPI, a fluorescent antibody to CD45 specific
to leucocytes and fluorescent antibodies to intracellular CK 8,
18 and 19. Sample analysis is performed by the Cell-Spotter
Analyzer, a four colour semi-automated fluorescence micro-
scope which identifies epithelial cells from being positive
for the CK markers and negative for the CD45 marker. Cell-
Search assay is more sensitive than the Oncoquick method45,
it is semi-automated and reduces trapping of leucocytes with
epithelial cells. Finally, it also allows cell counting. However,
cell isolation and detection are performed with antibodies
specific to epithelial cells (EpCAM, CK 8, 18 and 19). Actually,
it is well known that epithelial non-tumour cells can be
spread in the peripheral blood (by inflammation, cytokine
stimulating therapies, semi-surgical and surgical interven-
tions) making difficult to determine the actual number of
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circulating epithelial cells (CEpC). This is particularly relevant
when CTC counting is performed to assess the tumour re-
sponse to the therapy, the risk of developing tumour recur-
rence and in cancer screening protocols. The finding that
some CEpC identified in patients are characterised by aneu-
ploidy46 does not mean that any CEpC detected in any patient
is a CTC. As discussed previously, the most indifferentiated
CTC lose epithelial antigens (by EMT), and assays targeting
epithelial cells in blood are susceptible to missing the detec-
tion of the most invasive tumour cells. As a matter of fact, Ep-
CAM has been found to be expressed in only 70% of 134
tumours with different histologic types.47 Furthermore, CK
8, 18 and 19 were found to be lost in cell lines derived from
disseminated tumour cells.20 The loss of CK and the ectopic
expression of vimentin, indicating EMT, has been demon-
strated to be associated with a higher tumour grade andmito-
tic index, and with negative estrogen/progesterone receptor
status in 2517 breast cancers.20 Finally, CTM (circulating tu-
mour microemboli) cannot be reliably detected by this ap-
proach, as multiple cell labelling and treatments with
magnetic particles may induce dissociation of tumour cell
aggregates. Recently, the development of a unique microflu-
idic platform (the ‘CTC-chip’) was developed for the efficient
and selective separation of viable CTCs from peripheral whole
blood samples, mediated by the interaction of target CTCs
with antibody (EpCAM)-coated microposts under precisely
controlled laminar flow conditions, and without requisite
pre-labelling or processing of samples.48 The CTC-chip suc-
cessfully identified CTCs in the peripheral blood of patients
with metastatic lung, prostate, pancreatic, breast and colon
cancer in 115 of 116 (99%) samples, with a range of 5–
1,281CTCs per ml and approximately 50% purity. In addition,
CTCs were isolated in 7/7 patients with early-stage prostate
cancer. This example of microfluidic rare-cell capture tech-
nology applied to cancer patients hold significant promises
for identifying key biological determinants of blood-borne
metastases and providing a robust platform aimed at early
diagnosis and longitudinal monitoring of cancer.
A novel technique for the detection and ex vivo character-
isation of single viable disseminated tumour cells derived
from epithelial tumours, epithelial immuno-spot (EPISPOT),
has been recently reported49 based on the detection of spe-
cific secreted proteins by a modified protocol of enzyme-
linked immuno-spot assay. By means of this new assay the
authors demonstrated the viability of the CTC in patients af-
fected by prostate and breast cancer and their heterogeneity
with regard to the secretion of relevant proteins. This multi-
parameter technology reveals a unique fingerprint of proteins
secreted by single viable CTC and, if validated in large-scale
studies, can improve the understanding of the mechanisms
underlying the metastatic process.5. Direct methods
Direct methods are meant to provide a diagnostic identifica-
tion of CTC obtained by cytopathological analysis of the iso-
lated cells7 and/or by the analysis of their genome providing
clues to the cancer nature of the cells.38,46Cytopathological analysis can be carried out in a routine
manner, provided that CTC enrichment does not damage cell
morphology. In contrast, genome analyses (FISH, CGH, muta-
tion analysis) have not been applied routinely, for technical
reasons, to the detection of CTC, but rather to their
characterisation.46,50,51
Thus, there is a strong argument to be made that cytopath-
ological analysis should be the reference diagnostic method,
and be used to identify CTC and CTM, just as it is in other
oncological diagnostic settings (PAP-test, cytopathological
analysis of tumour biopsies and aspirates and of biological
liquids (ascites, urine, cephalo-rachidien liquid). Cytopatho-
logical analysis could be used as a reference basic approach
to recognise CTC/CTM, applying additional techniques (im-
muno-labelling, FISH, RNA/DNA analysis) to better character-
ise their malignant nature and their invasive potential.
In the past, the classical technique of blood smears has
been applied to perform cytopathological analysis of CTC.
However, this is not feasible as a routine manner, in order
to find one CTC in one ml of blood, the analysis of 100 smears
(10 ll per smear) must be performed.17
Enrichment approaches aimed at isolating CTC indepen-
dently from their antigens and avoiding damage to cell mor-
phology are based on physical properties of CTC: density
and size. After cytological staining (May-Grunwald Giemsa,
Hematoxylin & Eosin), cytoplasmic and nuclear details be-
come available to observation and thus allow cytopathologi-
cal diagnosis of CTC/CTM.
Direct enrichment of epithelial cells by filtration has been
first described by Vona et al. in 2000.52 Isolation by size of Epi-
thelial Tumour cells (ISET) (Metagenex, Paris France; http://
www.metagenex.fr) is based on the observation that the vast
majority of peripheral blood leucocytes (lymphocytes and
neutrophils) are the smallest cells in the body, having a size
ranging from 8 to 11 lm. They can thus be massively elimi-
nated by blood filtration through polycarbonate membranes
with calibrated pores of 8 lm.
The assay is simple and should reduce the loss of tumour
cells because it does not require multiple steps of isolation. In
this procedure, EDTA peripheral blood is diluted with the ISET
buffer (which fixates cells), and filtrated by the ISET device (2–
3 min). Filtration takes place through distinct spots on the fil-
ter according to the blood volume, so that every spot will
show the retained ‘large’ cells which were, before filtration,
in one ml of blood. This permits the precise counting of the
number of CTC per ml of blood independently from the vol-
ume treated. Enriched cells can be marked with cytological
staining (i.e. May-Grunwald Giemsa, Haematoxylin and Eo-
sin), and/or characterised by immuno-labelling, FISH, or TUN-
EL assays in order to analyse their antigens, aneuploidy and
the rate of apoptotic cells. Interestingly, CTM, which are
thought to carry a high metastatic potential, are also sensi-
tively enriched and can be reliably counted (Fig. 1). Molecular
analyses can be carried out after laser CTC/CTM microdissec-
tion. In a previous study, we53 used ISET followed by CK-19
staining of the enriched cells and demonstrated the feasibility
of studying the HER2 DNA amplification in tumour cells
microdissected after enrichment by ISET.
Alternatively, molecular analyses can be carried out by lys-
ing all the enriched cells on the spots. Enrichment by direct
Fig. 1 – Circulating tumour cell (a) and circulating tumour
microemboli (b) isolated by ISET from peripheral blood of a
patient affected by colon cancer.
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cannot cross the 8-micron pores.17 Furthermore, this direct
method avoids multiple steps and cell damage, both contrib-
uting to enrichment sensitivity.
Finally, the design of Metablock has been planned specifi-
cally to avoid cell loss, and has been shown to isolate one sin-
gle tumour cell added to 10 ml of blood by micropipetting (the
only way to reliably count the tumour cells added to blood) in
80% of the tests. This high sensitivity is maintained when
treating blood samples within 3–4 h after collection. It should
be pointed out that CTC are fragile and can be lysed by blood
storage, even if a conservative reagent is added.
The size of tumour cells from patients with solid cancers
(breast, colon, lung, prostate, liver, pancreas, ovary and many
others) tested up to now is not as small as that of lymphocytesFig. 2 – SEM pictures. (A) Commercial membrane filter with spars
membrane filter, (C) parylene membrane filter with cells captur
membrane filter with cells captured after SEM fixation procedurand neutrophils. Meng et al.54 reported that themean diameter
of tumour cells in blood frompatientswith breast cancer ranges
from 29.8 lm (patients with cancer dormancy) to 33.9 (patients
with metastatic cancer) and 32.0 lm (patients with primary tu-
mour). Since the cell morphology is conserved, it is easy to dis-
tinguish epithelial non-tumour cells from tumour cells by
cytological staining and cytopathological examination, comple-
mented if required by immuno-labelling. A limited number of
leucocytes are also retained on the filter, but they are very easy
to recognise without any additional labelling.
Ongoing and future ISET developments concerning auto-
mated image analysis on the filter and transmission of high
definition images through the web for ‘‘on line’’ cytopatholog-
ical consultations are aimed to speed up the work of cytopa-
thologists on CTC/CTM detection. Remarkably, images of
CTC/CTM found in the patient blood (and often characteristic
of individual patients) can be included in the patient file,
along with the assessment of their number, to provide oncol-
ogists with a visual aspect of this new marker and its evolu-
tion during follow-up (modification of CTC morphology
towards more malignant traits, appearance of CTM, appear-
ance of apoptotic cells).
Interest on the filtration approach to CTCs isolation is dem-
onstrated by recent paper studying extensively the filter struc-
ture and proposing newandmore efficient support to optimise
blood filtration.55 SEM pictures were taken for LNCaP cells iso-
lated on membrane filer (Fig. 2). Compared with commercially
available polycarbonate filters (Fig. 2A), the new parylene fil-
ters (Fig. 2B and C) are more dense and without fused pores.
The SEM fixation procedure (Fig. 2D) preserved the cell shapee and occasionally fused pores, (B) microfabricated parylene
ed without SEM fixation treatment and (D) parylene
e 55.
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grated in amicro-electro-mechanical system thatmake the fil-
tration process simpler, faster, better and cheaper. The size
difference between CTCs and human blood cells was investi-
gated to achieve the CTC capture on filter with 90% recovery
within 10 min, which is superior to current approaches.
A biochip aimed to separate cells based on their size and
ability to deform has been developed;56 even if its application
was limited to the isolation of foetal cells from maternal cir-
culation, which in concept resemble closely the situation of
CTC in patients affected by cancer.
6. Conclusion
The importance of tumour cells disseminated into bone mar-
row as an independent prognostic marker has been widely
confirmed. Recently, also the clinical significance of CTC in
peripheral blood has been proven. The process is completely
different, the detection of CTC in blood is a dynamic process,
whereas the presence of tumour cells in bone marrow might
be considered a static process. Tumour cells in bone marrow
are usually dormant and have a very long survival time be-
cause they are not destroyed be the body’s defence
mechanisms.
The challenge of CTC detection is related to the require-
ment of high sensitivity combined with high specificity. Since
invasion can start very early during tumour development,
identification and counting of CTC when they are very rare
(few CTC per 10 ml of blood, which means few CTC mixed
with approximately 100 million leucocytes and 50 billion
erythrocytes) could alert the oncologist about a developing tu-
mour invasion process. Specificity is also an absolute require-
ment in this field.
The detection of CTC correlates with pathological stage
and clinical outcome in particular in those patients with ad-
vanced disease. CTC levels before and after CT are an inde-
pendent prognostic factor for PFS and OS. One of the major
problem in this field is the reproducibility of the method. Sas-
tre et al., demonstrated that CTC research in CRC is highly
reproducible method that correlates with stage. RT-PCR and
other methods have been developed to detect the presence
of CTC, Mersh et al., suggested a positive prognostic value
of complete clearance of CTC after surgery to determinate
the patients who can benefit by chemotherapy. Future clinical
studies will evaluate the clinical significance of CTC in colo-
rectal cancer and in other tumours.Conflict of interest statement
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